Subgroups of HCV-infected patients with hematologic malignancies for whom DAA therapy is contraindicated
| The subgroups are as follows: . |
|---|
| Patients with uncontrolled hematologic malignancy or other comorbidities associated with a life expectancy of <12 months due to non–liver-related conditions* |
| Patients with moderate or severe hepatic impairment (Child-Pugh class B or C)† |
| Pregnant women and men whose female partners are pregnant if ribavirin is considered |
| Patients with major drug-drug interactions with chemotherapy or immunosuppressive agents that cannot be temporarily discontinued |
| Patients with known hypersensitivity or intolerance to drugs used to treat HCV |
| The subgroups are as follows: . |
|---|
| Patients with uncontrolled hematologic malignancy or other comorbidities associated with a life expectancy of <12 months due to non–liver-related conditions* |
| Patients with moderate or severe hepatic impairment (Child-Pugh class B or C)† |
| Pregnant women and men whose female partners are pregnant if ribavirin is considered |
| Patients with major drug-drug interactions with chemotherapy or immunosuppressive agents that cannot be temporarily discontinued |
| Patients with known hypersensitivity or intolerance to drugs used to treat HCV |
Extrapolated from recommendations in HCV-infected patients without cancer.12
While waiting for efficacy and safety data in infected patients with hematologic malignancies. Because liver transplantation is the only available treatment of decompensated cirrhosis,12,38 these patients should be managed by providers with expertise in that condition, ideally in a liver transplant center. Of note, incurable extrahepatic malignancies are considered a contraindication to listing for liver transplantation,39 therefore, some patients with hematologic malignancies may not be eligible for this intervention.